INICIO
QUIÉNES SOMOS
ÁREA PERSONAL
INICIO
QUIÉNES SOMOS
ÁREA PERSONAL
Login
Módulo 3
Página Principal
Cursos
Diploma de Experto en Medicina Personalizada y de Precisión
M3 2025
UD2. Biología y patología molecular en enfermedades neurodegenerativas
Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how
Salta al contenido principal
Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how
Haga clic en
PIIS1474442220300363.pdf
para ver el archivo.
◄ Imaging insights into basal ganglia function, Parkinson’s disease, and dystonia
Ir a...
Ir a...
Condiciones de participación y certificación
Foro General
Foro de la Ud1
Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. Diagn Pathol. 2023 Oct 3;18(1):109. doi: 10.1186/s13000-023-01375-z.
Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019 Nov;16(11):703-715. doi: 10.1038/s41571-019-0252-y.
Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019 May;20(5):e253-e261.
Liquid biopsy enters the clinic — implementation issues and future challenges.
Módulo 4 liquid biopsy summary.
Parkinson’s disease
A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria
Pharmacogenetics of Parkinson’s Disease in Clinical Practice
Imaging insights into basal ganglia function, Parkinson’s disease, and dystonia
Biomarkers of Parkinson’s disease: 20 years later
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
especialNuevos tratamientos en la enfermedad de Alzheimer. New treatments in Alzheimer’s disease
2024 Alzheimer’s disease facts and figures
Genetic Testing in Epilepsy: Improving Outcomes and Informing Gaps in Research
Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
Gene-based therapies for neuromuscular disorders
Editorial: Personalized medicine for neuromuscular disorders
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Pablo Mir
3.2. Cuestinario de conocimientos adquiridos
Biomarkers of Parkinson’s disease: 20 years later ►
Copyright © Consejería de Salud y Consumo - Junta de Andalucía. Todos los derechos reservados.
